top of page
pairx faded5.png

Next Generation
Cancer Immunotherapies

About us

PairX Bio Pte. Ltd. is developing next generation cancer immunotherapies targeting shared tumour-associated antigens derived from aberrantly spliced proteins. The PairX platform is built upon a deep understanding of mRNA splicing biology, which when combined with our proprietary antigen and T cell validation methods yield simultaneous validation of tumour antigen-T cell pairs in multiple patient derived tumours.

The technology was developed at Duke-NUS Medical School in Prof David Epstein’s lab (Founder & CEO of Black Diamond Therapeutics, Inc). The company was incubated by EVX Ventures and spun out from Duke-NUS. The founding investors are EVX Ventures and Avendesora (an investment company represented by Jeffrey Lu and Dr. Timothy Lu).

About us

We are now seeking for talented scientists to join our PairX team!

bottom of page